Lyell Immunopharma Key Executives
This section highlights Lyell Immunopharma's key executives, including their titles and compensation details.
Find Contacts at Lyell Immunopharma
(Showing 0 of )
Lyell Immunopharma Earnings
This section highlights Lyell Immunopharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
$0.54
Stock Price
$158.83M
Market Cap
300
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Lyell Immunopharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $61.00K | $130.00K | $84.68M | $10.65M | $7.76M |
| Cost of Revenue | $- | $- | $16.47M | $14.54M | $7.47M |
| Gross Profit | $61.00K | $130.00K | $68.22M | $-3.88M | $281.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 80.55% | -36.50% | 3.62% |
| Research and Development Expenses | $171.60M | $182.94M | $159.19M | $138.69M | $182.24M |
| General and Administrative Expenses | $52.04M | $66.98M | $117.31M | $89.06M | $46.88M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $52.04M | $66.98M | $117.31M | $89.06M | $46.88M |
| Other Expenses | $135.17M | $-2.79M | $1.89M | $-2.32M | $-9.43M |
| Operating Expenses | $358.82M | $247.14M | $276.50M | $225.43M | $219.69M |
| Cost and Expenses | $358.82M | $247.14M | $276.50M | $225.43M | $219.69M |
| Interest Income | $24.07M | $23.45M | $7.05M | $1.17M | $5.94M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $20.25M | $16.47M | $14.54M | $7.47M |
| EBITDA | $-3.31M | $-226.76M | $-166.65M | $-199.94M | $-207.64M |
| EBITDA Ratio | -5424.59% | -174429.23% | -194.96% | -1546.53% | -2677.19% |
| Operating Income | $-3.31M | $-247.01M | $-183.12M | $-214.78M | $-211.94M |
| Operating Income Ratio | -5424.59% | -190006.15% | -216.24% | -2016.68% | -2732.56% |
| Total Other Income Expenses Net | $-339.69M | $12.38M | $3.84M | $-36.65M | $7.46M |
| Income Before Tax | $-342.99M | $-234.63M | $-183.12M | $-250.22M | $-204.47M |
| Income Before Tax Ratio | -562285.25% | -180486.15% | -216.24% | -2349.47% | -2636.31% |
| Income Tax Expense | $- | $- | $-178.36M | $35.28M | $-5.94M |
| Net Income | $-342.99M | $-234.63M | $-4.75M | $-285.50M | $-198.53M |
| Net Income Ratio | -562285.25% | -180486.15% | -5.61% | -2680.76% | -2559.73% |
| EPS | $-1.31 | $-0.93 | $-0.02 | $-1.18 | $-0.81 |
| EPS Diluted | $-1.31 | $-0.93 | $-0.02 | $-1.18 | $-0.81 |
| Weighted Average Shares Outstanding | 261.48M | 250.98M | 247.08M | 242.74M | 246.58M |
| Weighted Average Shares Outstanding Diluted | 261.48M | 250.98M | 247.08M | 242.74M | 246.58M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.00K | $34.00K | $13.00K | $3.00K | $13.00K | $25.00K | $27.00K | $65.00K | $48.39K | $3.00K | $35.74M | $553.00K | $2.82M | $2.75M | $2.63M | $2.44M | $2.31M | $1.07M | $3.12M | $1.26M |
| Cost of Revenue | $- | $- | $4.90M | $5.02M | $5.06M | $5.10M | $4.54M | $5.03M | $4.59M | $4.17M | $3.73M | $3.97M | $3.99M | $- | $- | $3.00M | $- | $- | $- | $- |
| Gross Profit | $11.00K | $34.00K | $-4.89M | $-5.02M | $-5.04M | $-5.08M | $-4.51M | $-4.96M | $-4.54M | $-4.17M | $32.01M | $-3.42M | $-1.17M | $2.75M | $2.63M | $-553.00K | $2.31M | $1.07M | $3.12M | $1.26M |
| Gross Profit Ratio | 100.00% | 100.00% | -37600.00% | -167366.70% | -38800.00% | -20316.00% | -16711.10% | -7633.80% | -9390.30% | -138966.60% | 89.60% | -618.40% | -41.40% | 100.00% | 100.00% | -22.60% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $48.67M | $39.50M | $36.15M | $37.62M | $41.62M | $43.85M | $47.47M | $44.63M | $38.03K | $41.61M | $43.72M | $35.83M | $19.29M | $31.43M | $46.45M | $41.53M | $35.09M | $24.50M | $97.15M | $25.50M |
| General and Administrative Expenses | $14.52M | $11.77M | $12.26M | $13.49M | $13.17M | $15.51M | $19.03M | $19.28M | $26.35K | $26.08M | $30.45M | $34.42M | $31.87M | $21.24M | $19.11M | $16.83M | $14.87M | $13.57M | $9.56M | $8.88M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $14.52M | $11.77M | $12.26M | $13.49M | $13.17M | $15.51M | $19.03M | $19.28M | $26.35K | $26.08M | $30.45M | $34.42M | $31.87M | $21.24M | $19.11M | $16.83M | $14.87M | $13.57M | $9.56M | $8.88M |
| Other Expenses | $137.97M | $-730.00K | $-645.00K | $1.09M | $-506.00K | $1.58M | $-326.00K | $-1.29M | $3.54K | $-1.25M | $-14.00K | $-1.12M | $-44.00K | $16.00K | $-106.00K | $-27.00K | $46.00K | $28.00K | $29.00K | $1.42M |
| Operating Expenses | $201.16M | $50.54M | $48.41M | $51.12M | $54.79M | $59.06M | $65.93M | $62.62M | $67.92K | $66.44M | $73.00M | $69.13M | $50.36M | $51.92M | $65.33M | $57.81M | $41.84M | $37.91M | $105.68M | $34.26M |
| Cost and Expenses | $201.16M | $50.54M | $53.31M | $56.14M | $59.84M | $59.06M | $65.93M | $62.62M | $67.92K | $66.44M | $73.00M | $69.13M | $50.36M | $51.92M | $65.33M | $57.81M | $41.84M | $37.91M | $105.68M | $34.26M |
| Interest Income | $4.92M | $5.96M | $6.36M | $6.82M | $7.08M | $6.61M | $5.26M | $4.50M | $3.45K | $2.25M | $952.00K | $397.00K | $323.00K | $270.00K | $218.00K | $354.00K | $621.00K | $1.10M | $1.88M | $2.34M |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $65.67M | $- | $2.25M | $- | $397.00K | $323.00K | $270.00K | $218.00K | $354.00K | $621.00K | $1.10M | $1.88M | $2.34M |
| Depreciation and Amortization | $5.03M | $4.68M | $4.90M | $5.02M | $5.06M | $5.10M | $4.54M | $5.03M | $4.59M | $4.17M | $3.73M | $3.97M | $3.99M | $4.09M | $3.86M | $3.00M | $1.45M | $1.10M | $962.00K | $776.00K |
| EBITDA | $-57.64M | $-45.83M | $-46.63M | $-50.55M | $-54.01M | $-53.94M | $-60.84M | $-57.53M | $-9.74M | $-61.82M | $-33.09M | $-64.17M | $-42.00M | $-45.07M | $-59.70M | $-53.41M | $-38.07M | $-35.74M | $-101.60M | $-32.23M |
| EBITDA Ratio | -524000.00% | -134779.41% | -372276.92% | -1703866.67% | -421330.77% | -215740.00% | -214518.52% | -73121.54% | -6.94% | -1893866.67% | -92.58% | -11643.58% | -1522.79% | -1635.93% | -2271.58% | -2184.54% | -1646.71% | -3340.09% | -3258.63% | -2565.92% |
| Operating Income | $-201.15M | $-50.51M | $-53.30M | $-56.14M | $-59.83M | $-59.04M | $-65.91M | $-62.56M | $-8.40K | $-66.44M | $-37.26M | $-68.58M | $-47.54M | $-49.16M | $-62.71M | $-55.37M | $-39.52M | $-36.84M | $-102.57M | $-33.00M |
| Operating Income Ratio | -1828609.09% | -148544.12% | -409976.92% | -1871333.33% | -460230.77% | -236156.00% | -244092.59% | -96240.00% | -17.35% | -2214566.67% | -104.25% | -12400.72% | -1684.55% | -1784.43% | -2386.11% | -2264.62% | -1709.52% | -3443.27% | -3289.48% | -2627.71% |
| Total Other Income Expenses Net | $9.21M | $5.92M | $5.72M | $-5.09M | $6.14M | $8.19M | $2.02M | $-4.40M | $6.39M | $-3.82M | $938.00K | $348.00K | $-37.14M | $286.00K | $112.00K | $327.00K | $667.00K | $1.12M | $1.91M | $3.76M |
| Income Before Tax | $-191.94M | $-44.58M | $-45.81M | $-60.67M | $-52.93M | $-50.85M | $-63.89M | $-66.96M | $-8.40K | $-70.25M | $-36.32M | $-68.14M | $-83.71M | $-48.88M | $-62.59M | $-55.04M | $-38.86M | $-35.72M | $-100.66M | $-29.24M |
| Income Before Tax Ratio | -1744863.64% | -131126.47% | -352376.92% | -2022233.33% | -407153.85% | -203412.00% | -236629.63% | -103013.85% | -17.35% | -2341800.00% | -101.63% | -12322.60% | -2966.19% | -1774.05% | -2381.85% | -2251.25% | -1680.67% | -3338.22% | -3228.22% | -2328.03% |
| Income Tax Expense | $- | $- | $- | $4.98M | $5.01M | $-6.61M | $-2.34M | $65.67M | $-2.45M | $3.82M | $-952.00K | $-432.00K | $-323.00K | $-270.00K | $-218.00K | $-354.00K | $-1.29M | $-1.10M | $-1.88M | $-2.34M |
| Net Income | $-191.94M | $-44.58M | $-45.81M | $-60.67M | $-52.93M | $-50.85M | $-63.89M | $-132.63M | $2.44M | $-74.07M | $-36.32M | $-67.71M | $-83.71M | $-48.88M | $-62.59M | $-55.04M | $-38.86M | $-35.72M | $-100.66M | $-29.24M |
| Net Income Ratio | -1744863.64% | -131126.47% | -352376.92% | -2022233.33% | -407153.85% | -203412.00% | -236629.63% | -204046.15% | 5039.89% | -2469033.33% | -101.63% | -12244.48% | -2966.19% | -1774.05% | -2381.85% | -2251.25% | -1680.67% | -3338.22% | -3228.22% | -2328.03% |
| EPS | $-0.73 | $-0.17 | $-0.18 | $-0.24 | $-0.21 | $-0.20 | $-0.26 | $-0.53 | $0.01 | $-0.30 | $-0.15 | $-0.28 | $-0.35 | $-0.20 | $-1.47 | $-0.23 | $-0.18 | $-0.17 | $-0.48 | $-0.14 |
| EPS Diluted | $-0.73 | $-0.17 | $-0.18 | $-0.24 | $-0.21 | $-0.20 | $-0.26 | $-0.53 | $0.01 | $-0.30 | $-0.15 | $-0.28 | $-0.35 | $-0.20 | $-1.47 | $-0.23 | $-0.18 | $-0.17 | $-0.48 | $-0.14 |
| Weighted Average Shares Outstanding | 261.48M | 256.31M | 255.40M | 254.25M | 253.09M | 251.32M | 250.20M | 249.59M | 249.57M | 248.32M | 246.31M | 244.18M | 239.38M | 239.38M | 42.58M | 242.83M | 211.75M | 211.75M | 211.75M | 211.75M |
| Weighted Average Shares Outstanding Diluted | 261.48M | 256.31M | 255.40M | 254.25M | 253.09M | 251.32M | 250.20M | 249.59M | 249.57M | 248.32M | 246.31M | 244.18M | 239.38M | 239.38M | 42.71M | 242.83M | 211.75M | 211.75M | 211.75M | 211.75M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $105.60M | $145.65M | $123.55M | $293.83M | $140.41M |
| Short Term Investments | $264.93M | $400.58M | $516.60M | $320.97M | $472.21M |
| Cash and Short Term Investments | $370.53M | $546.22M | $640.15M | $614.79M | $612.62M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $9.07M | $8.46M | $11.14M | $22.98M | $4.93M |
| Total Current Assets | $379.59M | $554.69M | $651.29M | $626.29M | $617.55M |
| Property Plant Equipment Net | $72.94M | $142.32M | $166.26M | $166.64M | $124.06M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $19.00M | $48.51M | $115.04M | $330.53M | $163.44M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $19.33M | $4.52M | $4.96M | $3.95M | $3.23M |
| Total Non-Current Assets | $111.27M | $195.34M | $286.27M | $501.12M | $290.73M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $490.86M | $750.03M | $937.56M | $1.13B | $908.28M |
| Account Payables | $5.37M | $4.82M | $3.92M | $3.21M | $9.40M |
| Short Term Debt | $- | $6.27M | $4.53M | $1.17M | $3.62M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $21.87M | $4.99M | $6.09M |
| Other Current Liabilities | $48.42M | $23.43M | $28.58M | $37.37M | $30.18M |
| Total Current Liabilities | $53.79M | $34.52M | $37.03M | $46.74M | $49.28M |
| Long Term Debt | $50.99M | $56.89M | $126.34M | $133.30M | $50.96M |
| Deferred Revenue Non-Current | $- | $- | $- | $79.67M | $89.07M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.25M | $3.66M | $-59.05M | $-62.08M | $532.00K |
| Total Non-Current Liabilities | $54.25M | $60.56M | $67.28M | $150.88M | $140.56M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $108.03M | $95.08M | $104.31M | $197.62M | $189.84M |
| Preferred Stock | $- | $- | $- | $1.13B | $1.01B |
| Common Stock | $29.00K | $25.00K | $25.00K | $24.00K | $2.00K |
| Retained Earnings | $-1.35B | $-1.00B | $-767.48M | $-584.36M | $-334.14M |
| Accumulated Other Comprehensive Income Loss | $291.00K | $-94.00K | $-7.60M | $-1.62M | $256.00K |
| Other Total Stockholders Equity | $1.73B | $1.66B | $1.61B | $1.52B | $41.36M |
| Total Stockholders Equity | $382.82M | $654.95M | $833.25M | $929.79M | $718.44M |
| Total Equity | $382.82M | $654.95M | $833.25M | $929.79M | $718.44M |
| Total Liabilities and Stockholders Equity | $490.86M | $750.03M | $937.56M | $1.13B | $908.28M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $490.86M | $750.03M | $937.56M | $1.13B | $908.28M |
| Total Investments | $283.93M | $449.08M | $631.64M | $651.50M | $635.66M |
| Total Debt | $50.99M | $63.17M | $67.70M | $67.82M | $54.57M |
| Net Debt | $-54.60M | $-82.48M | $-55.85M | $-226.01M | $-85.83M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $105.60M | $100.30M | $133.42M | $125.65M | $145.65M | $286.21M | $224.37M | $109.43M | $123.55M | $116.31M | $205.74M | $222.60M | $293.83M | $393.50M | $564.44M | $244.37M | $140.41M | $-436.05M |
| Short Term Investments | $264.93M | $340.25M | $357.69M | $400.65M | $400.58M | $289.22M | $371.38M | $503.34M | $516.60M | $531.82M | $449.82M | $391.32M | $320.97M | $225.42M | $260.08M | $360.56M | $472.21M | $872.10M |
| Cash and Short Term Investments | $370.53M | $440.55M | $491.12M | $526.30M | $546.22M | $575.43M | $595.75M | $612.77M | $640.15M | $648.13M | $655.56M | $613.91M | $614.79M | $618.92M | $824.52M | $604.93M | $612.62M | $436.05M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $9.07M | $9.50M | $8.71M | $7.87M | $8.46M | $11.42M | $10.66M | $11.63M | $11.14M | $23.23M | $22.43M | $23.59M | $22.98M | $24.45M | $20.63M | $9.60M | $4.93M | $- |
| Total Current Assets | $379.59M | $450.05M | $499.82M | $534.16M | $554.69M | $586.85M | $606.41M | $624.40M | $651.29M | $659.75M | $666.78M | $625.71M | $626.29M | $631.15M | $834.84M | $609.74M | $617.55M | $436.05M |
| Property Plant Equipment Net | $72.94M | $124.71M | $130.79M | $136.53M | $142.32M | $148.70M | $155.19M | $160.99M | $166.26M | $169.81M | $172.47M | $171.43M | $166.64M | $163.09M | $158.06M | $144.87M | $124.06M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $32.01M | $39.11M | $19.29M | $19.29M | $48.51M | $54.73M | $68.95M | $90.18M | $115.04M | $144.52M | $178.44M | $271.12M | $330.53M | $400.96M | $233.71M | $118.65M | $163.44M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.31M | $5.35M | $4.24M | $4.24M | $4.52M | $4.71M | $4.80M | $4.88M | $4.96M | $3.19M | $3.99M | $3.85M | $3.95M | $3.13M | $3.26M | $3.93M | $3.23M | $-436.05M |
| Total Non-Current Assets | $111.27M | $169.17M | $154.32M | $160.06M | $195.34M | $208.13M | $228.94M | $256.05M | $286.27M | $317.52M | $354.90M | $446.40M | $501.12M | $567.19M | $395.03M | $267.45M | $290.73M | $-436.05M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $490.86M | $619.22M | $654.14M | $694.22M | $750.03M | $794.99M | $835.35M | $880.45M | $937.56M | $977.27M | $1.02B | $1.07B | $1.13B | $1.20B | $1.23B | $877.19M | $908.28M | $- |
| Account Payables | $5.37M | $3.60M | $4.20M | $4.89M | $4.82M | $4.37M | $5.80M | $5.73M | $3.92M | $4.79M | $4.25M | $6.51M | $3.21M | $3.53M | $4.86M | $7.12M | $9.40M | $- |
| Short Term Debt | $7.97M | $- | $- | $- | $6.27M | $- | $- | $- | $4.53M | $- | $- | $- | $1.17M | $- | $- | $- | $3.62M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $20.36M | $-6.06M | $-5.85M | $-4.81M | $21.87M | $11.19M | $15.43M | $6.22M | $4.99M | $5.58M | $8.23M | $7.92M | $6.09M | $- |
| Other Current Liabilities | $40.45M | $29.92M | $26.68M | $27.46M | $23.43M | $30.70M | $28.59M | $25.06M | $28.58M | $35.23M | $30.62M | $28.32M | $37.37M | $50.17M | $50.57M | $41.77M | $30.18M | $- |
| Total Current Liabilities | $53.79M | $33.51M | $30.88M | $32.35M | $34.52M | $35.06M | $34.39M | $30.80M | $37.03M | $51.22M | $50.29M | $41.05M | $46.74M | $59.28M | $63.66M | $56.81M | $49.28M | $- |
| Long Term Debt | $50.99M | $51.44M | $106.65M | $110.32M | $56.89M | $117.15M | $120.44M | $123.65M | $126.34M | $64.64M | $132.15M | $134.95M | $133.30M | $131.37M | $122.94M | $57.76M | $50.96M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $37.16M | $32.93M | $77.87M | $79.67M | $81.88M | $81.88M | $84.81M | $89.07M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.25M | $3.56M | $-49.88M | $-51.61M | $3.66M | $-54.80M | $-56.33M | $-57.83M | $-59.05M | $4.23M | $-61.73M | $-63.02M | $-62.08M | $-60.67M | $-60.57M | $893.00K | $89.60M | $- |
| Total Non-Current Liabilities | $54.25M | $55.01M | $56.76M | $58.71M | $60.56M | $62.35M | $64.11M | $65.83M | $67.28M | $106.03M | $103.34M | $149.80M | $150.88M | $152.58M | $144.25M | $143.46M | $140.56M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $108.03M | $88.52M | $87.64M | $91.06M | $95.08M | $97.42M | $98.50M | $96.62M | $104.31M | $157.24M | $153.63M | $190.85M | $197.62M | $211.86M | $207.91M | $200.27M | $189.84M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $1.20B | $1.23B | $1.01B | $1.01B | $519.16M |
| Common Stock | $29.00K | $26.00K | $26.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $24.00K | $24.00K | $24.00K | $2.00K | $2.00K | $- |
| Retained Earnings | $-1.35B | $-1.15B | $-1.11B | $-1.06B | $-1.00B | $-949.18M | $-898.33M | $-834.44M | $-767.48M | $-759.08M | $-688.83M | $-652.51M | $-584.36M | $-500.66M | $-451.78M | $-389.19M | $-334.14M | $- |
| Accumulated Other Comprehensive Income Loss | $291.00K | $760.00K | $-397.00K | $-404.00K | $-94.00K | $-1.18M | $-2.38M | $-3.88M | $-7.60M | $-10.00M | $-8.35M | $-6.60M | $-1.62M | $-65.00K | $73.00K | $163.00K | $256.00K | $-111.11M |
| Other Total Stockholders Equity | $1.73B | $1.68B | $1.68B | $1.67B | $1.66B | $1.65B | $1.64B | $1.62B | $1.61B | $1.59B | $1.57B | $1.54B | $1.52B | $1.49B | $1.47B | $54.97M | $41.36M | $- |
| Total Stockholders Equity | $382.82M | $530.70M | $566.50M | $603.16M | $654.95M | $697.57M | $736.86M | $783.83M | $833.25M | $820.03M | $868.04M | $881.25M | $929.79M | $986.47M | $1.02B | $676.92M | $718.44M | $408.06M |
| Total Equity | $382.82M | $530.70M | $566.50M | $603.16M | $654.95M | $697.57M | $736.86M | $783.83M | $833.25M | $820.03M | $868.04M | $881.25M | $929.79M | $986.47M | $1.02B | $676.92M | $718.44M | $408.06M |
| Total Liabilities and Stockholders Equity | $490.86M | $619.22M | $654.14M | $694.22M | $750.03M | $794.99M | $835.35M | $880.45M | $937.56M | $977.27M | $1.02B | $1.07B | $1.13B | $1.20B | $1.23B | $877.19M | $908.28M | $408.06M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $490.86M | $619.22M | $654.14M | $694.22M | $750.03M | $794.99M | $835.35M | $880.45M | $937.56M | $977.27M | $1.02B | $1.07B | $1.13B | $1.20B | $1.23B | $877.19M | $908.28M | $408.06M |
| Total Investments | $296.94M | $379.36M | $376.98M | $419.94M | $449.08M | $321.22M | $403.38M | $538.27M | $631.64M | $676.34M | $628.26M | $662.43M | $651.50M | $626.38M | $493.79M | $479.21M | $635.66M | $872.10M |
| Total Debt | $58.97M | $51.44M | $60.22M | $61.83M | $63.17M | $58.58M | $60.22M | $61.83M | $67.70M | $64.64M | $66.07M | $67.47M | $67.82M | $65.68M | $61.47M | $57.76M | $54.57M | $- |
| Net Debt | $-46.63M | $-48.86M | $-73.20M | $-63.82M | $-82.48M | $-227.64M | $-164.15M | $-47.60M | $-55.85M | $-51.67M | $-139.66M | $-155.12M | $-226.01M | $-327.82M | $-502.97M | $-186.61M | $-85.83M | $436.05M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-342.99M | $-234.63M | $-183.12M | $-250.22M | $-204.47M |
| Depreciation and Amortization | $19.63M | $20.25M | $18.02M | $13.62M | $4.29M |
| Deferred Income Tax | $- | $- | $2.32M | $39.51M | $-5.61M |
| Stock Based Compensation | $33.14M | $47.08M | $81.92M | $62.20M | $33.26M |
| Change in Working Capital | $-3.12M | $3.42M | $-82.02M | $4.01M | $-336.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-3.23M | $1.46M | $667.00K | $91.00K | $-278.00K |
| Other Working Capital | $114.00K | $1.96M | $-82.68M | $3.92M | $-58.00K |
| Other Non Cash Items | $130.94M | $183.00K | $-6.68M | $4.62M | $11.99M |
| Net Cash Provided by Operating Activities | $-162.39M | $-163.69M | $-169.56M | $-126.25M | $-160.87M |
| Investments in Property Plant and Equipment | $-464.00K | $-2.69M | $-24.28M | $-65.50M | $-51.48M |
| Acquisitions Net | $- | $-186.73M | $-12.74M | $673.47M | $- |
| Purchases of Investments | $-394.71M | $-476.88M | $-406.32M | $-673.47M | $-43.45M |
| Sales Maturities of Investments | $548.94M | $663.61M | $419.05M | $617.40M | $686.32M |
| Other Investing Activities | $-31.35M | $186.73M | $12.74M | $-673.47M | $-864.91M |
| Net Cash Used for Investing Activities | $122.42M | $184.05M | $-11.54M | $-121.57M | $-273.52M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $2.20M | $9.58M | $391.80M | $- |
| Common Stock Repurchased | $36.01M | $-457.00K | $-461.00K | $- | $-16.05M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.33M | $1.74M | $10.63M | $9.44M | $488.60M |
| Net Cash Used Provided by Financing Activities | $1.33M | $1.74M | $10.63M | $401.24M | $476.79M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-38.64M | $22.10M | $-170.46M | $153.42M | $42.40M |
| Cash at End of Period | $107.29M | $145.93M | $123.83M | $294.29M | $140.87M |
| Cash at Beginning of Period | $145.93M | $123.83M | $294.29M | $140.87M | $98.47M |
| Operating Cash Flow | $-162.39M | $-163.69M | $-169.56M | $-126.25M | $-160.87M |
| Capital Expenditure | $-464.00K | $-2.69M | $-24.28M | $-65.50M | $-51.48M |
| Free Cash Flow | $-162.86M | $-166.38M | $-193.83M | $-191.75M | $-212.35M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-191.94M | $-44.58M | $-45.81M | $-60.67M | $-52.93M | $-50.85M | $-63.89M | $-66.96M | $-8.40M | $-70.25M | $-36.32M | $-68.14M | $-83.71M | $-48.88M | $-62.59M | $-55.04M | $-38.86M | $-35.72M | $-100.66M | $-29.24M |
| Depreciation and Amortization | $5.03M | $4.68M | $4.90M | $5.02M | $5.06M | $5.10M | $5.06M | $5.03M | $5.04M | $4.62M | $4.17M | $4.19M | $4.57M | $4.09M | $3.01M | $1.96M | $1.45M | $1.10M | $962.00K | $776.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-18.15M | $-1.65M | $1.28M | $- | $93.90M | $- | $- | $- | $37.38M | $1.09M | $996.00K | $43.00K | $-4.38M | $213.00K | $-61.00K | $-1.38M |
| Stock Based Compensation | $8.08M | $7.62M | $8.28M | $9.15M | $8.46M | $10.52M | $14.22M | $13.88M | $18.36M | $19.12M | $22.41M | $22.03M | $21.18M | $13.04M | $15.25M | $12.73M | $12.97M | $9.75M | $7.27M | $3.27M |
| Change in Working Capital | $34.00K | $1.04M | $-954.00K | $-3.24M | $1.72M | $2.43M | $3.58M | $-4.31M | $-43.39M | $1.75M | $-37.98M | $-2.39M | $3.62M | $5.74M | $-565.00K | $-4.78M | $2.11M | $371.00K | $-2.27M | $-546.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.04M | $-568.00K | $-517.00K | $-113.00K | $425.00K | $-1.41M | $380.00K | $2.07M | $-526.00K | $23.00K | $-1.77M | $2.94M | $99.00K | $-988.00K | $346.00K | $634.00K | $338.00K | $-293.00K | $-1.24M | $921.00K |
| Other Working Capital | $2.07M | $1.60M | $-437.00K | $-3.12M | $1.30M | $3.84M | $3.20M | $-6.38M | $-42.87M | $1.73M | $-35.74M | $-5.33M | $3.52M | $6.73M | $-911.00K | $-5.41M | $1.77M | $664.00K | $-1.03M | $-1.47M |
| Other Non Cash Items | $131.55M | $-3.80M | $14.09M | $27.02M | $15.21M | $-3.23M | $582.00K | $6.15M | $-105.78M | $7.66M | $3.15M | $-3.53M | $-16.20M | $-619.00K | $9.96M | $11.49M | $-25.00K | $2.65M | $5.84M | $3.52M |
| Net Cash Provided by Operating Activities | $-47.24M | $-35.04M | $-38.09M | $-42.02M | $-40.63M | $-37.69M | $-39.16M | $-46.21M | $-40.27M | $-37.10M | $-44.33M | $-47.85M | $-33.17M | $-25.53M | $-33.95M | $-33.60M | $-26.73M | $-21.63M | $-88.92M | $-23.59M |
| Investments in Property Plant and Equipment | $-44.00K | $-59.00K | $-331.00K | $-30.00K | $-25.00K | $-195.00K | $-933.00K | $-1.53M | $-4.58M | $-2.79M | $-7.17M | $-9.73M | $-10.27M | $-11.60M | $-24.45M | $-19.19M | $-24.88M | $-12.64M | $-7.08M | $-6.88M |
| Acquisitions Net | $- | $- | $- | $- | $100.67M | $78.28M | $33.26M | $-33.69M | $- | $160.79M | $- | $96.20M | $-40.00K | $- | $40.00K | $- | $- | $- | $- | $- |
| Purchases of Investments | $-38.80M | $-131.43M | $-116.46M | $-108.01M | $-256.79M | $-78.28M | $-33.26M | $-108.56M | $-220.46M | $-160.79M | $-89.66M | $-96.20M | $-673.47M | $-275.31M | $-215.94M | $-48.29M | $-7.00M | $- | $- | $- |
| Sales Maturities of Investments | $123.70M | $133.41M | $161.80M | $130.03M | $156.12M | $178.15M | $187.10M | $142.25M | $110.90M | $106.50M | $121.85M | $79.81M | $70.33M | $142.04M | $200.87M | $204.16M | $205.69M | $173.10M | $177.70M | $129.83M |
| Other Investing Activities | $-31.35M | $- | $45.34M | $22.02M | $-100.67M | $-78.28M | $-33.26M | $33.69M | $160.79M | $-160.79M | $32.19M | $-96.20M | $539.50M | $-275.31M | $-215.90M | $-48.29M | $-141.42M | $-250.40M | $-270.50M | $-239.03M |
| Net Cash Used for Investing Activities | $53.51M | $1.92M | $45.01M | $21.99M | $-100.69M | $99.67M | $152.91M | $32.15M | $46.65M | $-57.09M | $25.02M | $-26.12M | $-73.90M | $-144.87M | $-39.47M | $136.68M | $32.39M | $-89.94M | $-99.88M | $-116.08M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-965.00K | $862.00K | $103.00K | $882.00K | $72.00K | $1.25M | $- | $9.58M | $5.13M | $1.57M | $2.56M | $10.50M | $-531.00K | $393.49M | $884.00K | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-734.00K | $810.00K | $-76.00K | $-123.00K | $-215.00K | $-50.00K | $-69.00K | $-94.00K | $-367.00K | $- | $- | $- | $-531.00K | $- | $- | $- | $- | $- | $-16.05M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $437.00K | $103.00K | $862.00K | $27.00K | $759.00K | $-143.00K | $1.20M | $-69.00K | $863.00K | $4.76M | $2.46M | $2.56M | $7.40M | $529.00K | $630.00K | $884.00K | $338.00K | $35.00K | $-2.00K | $488.23M |
| Net Cash Used Provided by Financing Activities | $437.00K | $- | $862.00K | $27.00K | $759.00K | $-143.00K | $1.20M | $-69.00K | $863.00K | $4.76M | $2.46M | $2.56M | $7.40M | $-531.00K | $393.49M | $884.00K | $338.00K | $35.00K | $-2.00K | $476.42M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-1.00K | $-102.39M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $6.70M | $-33.12M | $7.77M | $-20.00M | $-140.57M | $61.84M | $114.95M | $-14.13M | $7.24M | $-89.43M | $-16.86M | $-71.42M | $-99.68M | $-170.94M | $320.07M | $103.96M | $5.99M | $-111.54M | $-188.80M | $336.75M |
| Cash at End of Period | $107.29M | $100.59M | $133.42M | $125.65M | $145.65M | $286.50M | $224.65M | $109.71M | $123.83M | $116.59M | $206.02M | $222.88M | $294.29M | $393.97M | $564.91M | $244.84M | $140.87M | $134.88M | $246.42M | $435.22M |
| Cash at Beginning of Period | $100.59M | $133.71M | $125.65M | $145.65M | $286.21M | $224.65M | $109.71M | $123.83M | $116.59M | $206.02M | $222.88M | $294.29M | $393.97M | $564.91M | $244.84M | $140.87M | $134.88M | $246.42M | $435.22M | $98.47M |
| Operating Cash Flow | $-47.24M | $-35.04M | $-38.09M | $-42.02M | $-40.63M | $-37.69M | $-39.16M | $-46.21M | $-40.27M | $-37.10M | $-44.33M | $-47.85M | $-33.17M | $-25.53M | $-33.95M | $-33.60M | $-26.73M | $-21.63M | $-88.92M | $-23.59M |
| Capital Expenditure | $-44.00K | $-59.00K | $-331.00K | $-30.00K | $-25.00K | $-195.00K | $-933.00K | $-1.53M | $-4.58M | $-2.79M | $-7.17M | $-9.73M | $-10.27M | $-11.60M | $-24.45M | $-19.19M | $-24.88M | $-12.64M | $-7.08M | $-6.88M |
| Free Cash Flow | $-47.29M | $-35.10M | $-38.42M | $-42.05M | $-40.66M | $-37.88M | $-40.09M | $-47.74M | $-44.85M | $-39.89M | $-51.50M | $-57.59M | $-43.44M | $-37.13M | $-58.39M | $-52.79M | $-51.61M | $-34.27M | $-96.00M | $-30.47M |
Lyell Immunopharma Dividends
Explore Lyell Immunopharma's dividend history, including dividend yield, payout ratio, and historical payments.
Lyell Immunopharma News
Read the latest news about Lyell Immunopharma, including recent articles, headlines, and updates.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences: H.C.
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced pipeline updates, including its plans to advance IMPT-314, a potentially best-in-class therapy for aggressive large B-cell lymphoma, into pivotal trials. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19‑targeted CAR therapies for the treatment of large B-cell lymphoma.
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced initial positive clinical data from the multi-center Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma that is being presented at the 66th American Society of Hematology (ASH) Annual Meeting. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin lymphoma.
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Sarah M. Larson, M.D., Associate Professor, Department of Medicine, Medical Director, Immune Effector Cell Therapy Program, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, at the 66th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA, December 7 – 10, 2024. IMPT-314 is a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin's lymphoma.
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, announced today that it has completed its acquisition of ImmPACT Bio USA Inc. (“ImmPACT”), a privately-owned clinical-stage cell therapy company. The acquisition strengthens Lyell's clinical-stage pipeline of CAR T-cell therapies and complements its suite of innovative technologies designed to generate longer-lasting, functional T cells to achieve more durable outcomes for patients. Lyell will accelerate the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma. In connection with the acquisition, Sumant Ramachandra, M.D., Ph.D., MBA, the former Chief Executive Officer of ImmPACT Bio, has been appointed to the Lyell Board of Directors.
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
Lyell Immunopharma, Inc.'s financials show reduced losses and efficient cash management, with a strong cash position supporting operations through 2027 despite a challenging biotech environment. The company's innovative CAR T-cell therapies, particularly LYL119 and IMPT-314, target critical oncology challenges with promising early clinical results expected by late 2025. Lyell's acquisition of ImmPACT Bio expands its pipeline into hematologic cancers, enhancing its portfolio with dual-targeting CAR T-cell therapies and broadening therapeutic options.
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to acquire ImmPACT Bio USA Inc. (“ImmPACT”), a privately-owned clinical-stage biotechnology company. ImmPACT's lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate that Lyell will continue to develop for hematologic malignancies, including large B-cell lymphoma. IMPT-314 was designed to outperform the efficacy of approved CD19 CAR T-cell therapies via a dual-targeting CAR T-cell design and to improve CAR T-cell persistence by enriching for naïve and central memory T cells during manufacturing. The acquisition of ImmPACT is expected to significantly strengthen Lyell's clinical-stage pipeline of next- generation CAR T-cell therapies and complement its suite of proprietary technologies designed to generate longer-lasting, functional T cells to achieve more durable outcomes for patients with solid tumors and hematologic malignancies.
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that three abstracts highlighting its pipeline of clinical product candidates and anti-exhaustion technology have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Houston, TX, Nov. 6-10, 2024.
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that Lynn Seely, MD, Lyell's President & CEO, will participate on a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1 at 11:50 a.m. ET.
Lyell Immunopharma Announces Participation in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences:
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, today reported financial results and business highlights for the second quarter ended June 30, 2024.
3 Biotech Stocks to Sell in August Before They Crash & Burn
For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and Drug Administration approval to rush a stock into the headlines rapidly.
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology. The initial dataset consists primarily of patients with triple-negative breast cancer (TNBC) and demonstrated dose-dependent antitumor clinical activity and the ability of LYL797 CAR T cells to proliferate, infiltrate tumors and kill cancer cells in patients with relapsed/refractory disease. Patients with TNBC treated with LYL797 had an objective response rate (ORR) of 40% and clinical benefit rate (CBR) of 60% at the 150 x 106 CAR T cell dose level, with a CBR of 38% across all dose levels evaluable to date. Common treatment-related adverse events in patients without lung metastases included Grade 1 and 2 cytokine release syndrome (CRS) and headache, and the expected cytopenia from lymphodepletion. There were no reports of immune effector cell-associated neurotoxicity syndrome (ICANS) attributed to LYL797. Pneumonitis occurred in patients with lung metastases and dose escalation is continuing separately and more gradually in those patients. No dose-limiting toxicities have been reported in patients without lung involvement. All patients are now receiving prophylactic steroids prior to LYL797 treatment.
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET.
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT.
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024.
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results expected in the first half of 2024 and the second half of this year.
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023.
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate the following upcoming investor conferences:
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 8:15 am Pacific Time.
Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL
Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients with relapsed/refractory metastatic or advanced melanoma, NSCLC, and colorectal cancer are expected in 2024. Lyell Immunopharma is advancing a 2nd generation CAR-T known as LYL119 and an IND submission for it is expected in 1st half of 2024. It is also advancing a second-generation TIL.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LYEL.